NCT02989194: A trial that was reported late by Visterra, Inc.
This trial has reported, although it was 571 days late in doing so.
Full data
| Full entry on ClinicalTrials.gov | NCT02989194 |
|---|---|
| Title | A Phase 2a Double-blind, Placebo-controlled Study to Assess the Safety and Tolerability of a Single Intravenous Dose of an Investigational Monoclonal Antibody With Code Name VIS410 in Subjects With Uncomplicated Influenza A Infection |
| Results Status | Reported (late) |
| ACT or pACT? | This is what FDAAA officially calls a "probable Applicable Clinical Trial" |
| Start date | Jan. 6, 2017 |
| Completion date | Oct. 27, 2017 |
| Required reporting date | Oct. 27, 2018, midnight |
| Actual reporting date | May 20, 2020 |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | 571 |